The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia

dc.contributor.authorSelva-Vera, Gabriel
dc.contributor.authorBalanzá-Martínez, Vicent
dc.contributor.authorSalazar-Fraile, José
dc.contributor.authorSánchez-Moreno, José
dc.contributor.authorMartínez-Arán, Anabel, 1971-
dc.contributor.authorCorrea, Patricia
dc.contributor.authorVieta i Pascual, Eduard, 1963-
dc.contributor.authorTabarés-Seisdedos, Rafael
dc.date.accessioned2014-02-21T10:29:37Z
dc.date.available2014-02-21T10:29:37Z
dc.date.issued2010-06-15
dc.date.updated2014-02-21T10:29:37Z
dc.description.abstractBACKGROUND: Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. METHODS: In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel antipsychotics (n = 26) at baseline and at two years after. RESULTS: Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, executive functions, and visual and verbal memory. Patients taking atypical antipsychotics did not show greater cognitive enhancement over two years than patients taking conventional antipsychotics. CONCLUSIONS: Although long-term antipsychotic treatment slightly improved cognitive function, the switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of these cognitive deficits.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec581131
dc.identifier.issn1471-244X
dc.identifier.pmid20550658
dc.identifier.urihttps://hdl.handle.net/2445/50488
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1186/1471-244X-10-47
dc.relation.ispartofBMC Psychiatry, 2010, vol. 10, p. 47
dc.relation.urihttp://dx.doi.org/10.1186/1471-244X-10-47
dc.rightscc-by (c) Selva-Vera, G. et al., 2010
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Psicologia Clínica i Psicobiologia)
dc.subject.classificationEsquizofrènia
dc.subject.classificationTrastorns de la cognició
dc.subject.classificationAntipsicòtics
dc.subject.otherSchizophrenia
dc.subject.otherCognition disorders
dc.subject.otherAntipsychotic drugs
dc.titleThe switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
581131.pdf
Mida:
785.77 KB
Format:
Adobe Portable Document Format